US Cannabis Grow Facilities Provider FutureLand Buys 20% of Apotheca Biosciences.
M2 EQUITYBITES-October 16, 2017-US Cannabis Grow Facilities Provider FutureLand Buys 20% of Apotheca Biosciences
(C)2017 M2 COMMUNICATIONS http://www.m2.com
16 October 2017 - Colorado, US-based recreational cannabis industry real estate investment and grow facilities provider FutureLand Corp. (OTC: FUTL) has purchased a 20% interest in Apotheca Biosciences for an undisclosed amount from CB Scientific, Inc. (OTC: CBSC), the company said.
Apotheca Biosciences is developing cannabinoids medical products, nutraceuticals, formulation and drug delivery technologies for the healthcare and consumer care industry.
Their pipeline of products includes, transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.
The last two decades of research have brought a tremendous improvement in knowledge of the endocannabinoid system (eCB system) components and functions under physiological and pathological conditions.
The eCB is a neuromodulatory system which consists of two subtypes of cannabinoid receptors, CB1 and CB2.
CB1 receptors are the most abundant in the central neural system, expressed in both neurons and glial cells, where they regulate important brain functions including cognition and memory, emotion, motor control, feeding, and pain perception.
FutureLand is a cannabis and hemp specialty zoned land leasing company formed to capitalise upon the emerging global cannabis market.
The company focuses on target acquisition, zoning, license fulfillment, site plan preparation and financing of cannabis or hemp grow facilities throughout the United States.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Oct 16, 2017|
|Previous Article:||European Wealth Group to Acquire US Broker Dealer Platform.|
|Next Article:||Angel Investor Zillionize Acquires Software Startup SilverSiphon.|